Behavior disorders in persons with mental retardation receiving antipsychotic medication.

Ono (1998) looked at the adults with intellectual disability living in Japanese facilities. Half took daily antipsychotics, half did not.

Staff filled out the Japanese Aberrant Behavior Checklist (ABC-J) for every resident. The team compared scores between the two groups.

The medicated group scored higher on every ABC-J subscale. More medication meant more hyperactivity.

In plain numbers: the higher the dose, the worse the hyperactivity score, even after age and IQ were held constant.

Silverman et al. (1994) saw no extra movement disorders when UK adults with learning disabilities took antipsychotics within British dosing rules. Y’s 1998 study shows more behavior problems, not less, when the drugs are used in Japanese facilities.

The two papers do not truly clash. K tracked physical side-effects under tight UK guidelines; Y tracked everyday challenging behavior in routine Japanese care, where doses may have been higher or paired with different routines.

de Bildt et al. (2003) later showed the ABC catches unique risk flags that other screens miss. Y’s early data remind us that high ABC scores can reflect both drug effects and unmet environmental needs.

If you serve adults with ID who take antipsychotics, do not assume the drug is controlling behavior. High ABC-J scores may signal over-medication, poor environmental fit, or both. Start by plotting dose against hyperactivity items each quarter. If scores climb with dose, bring the data to the prescribing doctor and request a med review plus a functional assessment. Pair any taper with increased activity choice and visual schedules—skills, not pills, may be the missing piece.